BioPharma Management and Consulting
De berekende faillissementskans van BioPharma Management and Consulting over 12 maanden bedraagt 0,4% (zeer laag). Het bedrijf is actief sinds 2016 en het Belgisch Staatsblad bevat geen insolventie- of waarschuwingssignalen. Er zijn geen verwerkte jaarrekeningcijfers beschikbaar; deze conclusie steunt uitsluitend op register- en Staatsbladgegevens.
| Actief | 9 jaar |
| Vestigingen | 1 |
| Publicaties | 1 |
Statistische inschatting op basis van openbare bronnen, geen kredietadvies of vaststelling. Hoe berekenen we dit?
| Boekjaar | Type | Neerlegging | Referentie |
|---|---|---|---|
| 31-12-2024 | micro | 28-02-2025 | 2025-00043206 |
| 31-12-2023 | micro | 04-10-2024 | 2024-00497235 |
| 31-12-2022 | micro | 29-03-2023 | 2023-00051012 |
| 31-12-2021 | micro | 26-05-2022 | 2022-20035376 |
| 31-12-2020 | micro | 25-05-2021 | 2021-15300390 |
| 31-12-2019 | micro | 28-05-2020 | 2020-13500340 |
| 31-12-2018 | micro | 08-10-2019 | 2019-69600176 |
| 31-12-2017 | micro | 31-07-2018 | 2018-42700392 |
| 31-12-2016 | volledig | 27-06-2017 | 2017-22400114 |
| NACE primair | Overige zakelijke dienstverlening, neg(82990) |
| Rechtsvorm | BV(610) |
| Oprichtingsdatum | 17-10-2016 |
| Status | Actief |
| Postcode | 5650 |
Elke band vermeldt waarop de claim steunt. Een bestuurszetel is invloed op het bestuur, geen eigendom. Gerechtelijke mandaten (curator, voorlopig bewindvoerder) en vereffeningsmandaten verbinden bedrijven niet en staan hier daarom niet in; ze horen bij Bestuurders & mandaten.
Percelen gekoppeld aan dit bedrijf via zijn adressen in de KBO (zetel, vestigingen, bijkantoren), gekruist met het kadastraal percelenplan. Dit toont waar het bedrijf actief is, geen eigendomsregister.
| Perceel (capakey) | Regio | Oppervlakte | Gebouwen | Hoogte / verd. |
|---|---|---|---|---|
| 93012A0125/00G000 | Wallonië | 1,9 ha | 1 · 299 m² | - |
Eén tijdlijn van alles wat er met dit bedrijf is gebeurd, publicaties, insolventie- en levensloopgebeurtenissen, administratieve wijzigingen en neergelegde jaarrekeningen.
Wij kennen 2 Staatsblad-aktes van dit bedrijf. Daarvan is er nog geen enkele gelezen: wat erin staat, is hier niet vastgesteld en ook niet weerlegd.
28-03-2024 Act object · Notarial deed · General meeting · Approval
- Act object: DEMISSIONS, NOMINATIONS · Ncardia Holding
- Publication: 28/03/2024 · Ncardia Holding
- Filing: 26-03-2024 · Ncardia Holding
- Notarial deed: 20 mars 2024 · Ncardia Holding
- General meeting: 20 mars 2024 · Ncardia Holding
- Approval: rapport du conseil d’administration · Ncardia Holding
- Statute amendment: modification des droits de nomination et de désignation du conseil d’administration (article 14.1) · Ncardia Holding
- Statute amendment: remplacement de la référence à 'Société Régionale d'Investissement de Wallonie SA' par 'Wallonie Entreprendre SA' dans les statuts · Ncardia Holding
- Statute amendment: coordination des articles 11, 14, 15 et 45 des statuts · Ncardia Holding
- Officer resignation: role: administrateur investisseur · BioPharma Management and Consulting
- Officer resignation: role: administrateur minoritaire · Sparaxis
- Officer resignation: role: administrateur minoritaire · A Q Invest
- Officer resignation: role: administrateur · Stefan Braam
- Officer appointment: role: administrateur investisseur, start_date: 2024-03-20 · Tim van Biesen
- Officer appointment: role: administrateur minoritaire, start_date: 2024-03-20 · BioPharma Management and Consulting
- Permanent representative · Denis Bedoret
- Officer appointment: role: administrateur exécutif, start_date: 2024-03-20 · Gustavo Mahler
- Officer appointment: role: Chief Executive Officer, start_date: 2024-03-20 · Gustavo Mahler
- Officer appointment: role: administrateur exécutif, start_date: 2024-03-20 · Stefan Braam
- Officer appointment: role: observateur, start_date: 2024-03-20 · Géry Lefebvre
- Power of attorney: remplir toute formalité administrative relative à la société auprès des guichets d’entreprises, du greffe du tribunal d’entreprise, et des services de la taxe sur la valeur ajoutée, de compléter le registre des actions et le signer · Timothy Speelman
Technische details
{
"facts": [
{
"type": "act_object",
"quote": "Objet de l\u0027acte : DEMISSIONS, NOMINATIONS",
"value": "DEMISSIONS, NOMINATIONS",
"object": null,
"subject": "e1"
},
{
"date": "2024-03-28",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 28/03/2024 - Annexes du Moniteur belge",
"value": "28/03/2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-03-26",
"type": "filing",
"quote": "D\u00E9pos\u00E9 26-03-2024",
"value": "26-03-2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-03-20",
"type": "notarial_deed",
"quote": "proc\u00E8s-verbal dress\u00E9 par Ma\u00EEtre Morgane DEVRIESE ... le 20 mars 2024",
"value": "20 mars 2024",
"object": "e2",
"subject": "e1"
},
{
"date": "2024-03-20",
"type": "general_meeting",
"quote": "l\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire des actionnaires ... a pris les r\u00E9solutions suivantes",
"value": "20 mars 2024",
"object": null,
"subject": "e1"
},
{
"type": "approval",
"quote": "Premi\u00E8re r\u00E9solution : approbation du rapport ... d\u00E9cide d\u0027adh\u00E9rer aux conclusions y formul\u00E9es",
"value": "rapport du conseil d\u2019administration",
"object": null,
"subject": "e1"
},
{
"type": "statute_amendment",
"quote": "Deuxi\u00E8me r\u00E9solution ... modifier les droits de nomination et de d\u00E9signation du conseil d\u2019administration tels qu\u2019ils figurent \u00E0 l\u2019article 14.1 des statuts",
"value": "modification des droits de nomination et de d\u00E9signation du conseil d\u2019administration (article 14.1)",
"object": null,
"subject": "e1"
},
{
"type": "statute_amendment",
"quote": "Troisi\u00E8me r\u00E9solution ... r\u00E9f\u00E9rence \u00E0 la \u0027Soci\u00E9t\u00E9 R\u00E9gionale d\u0027Investissement de Wallonie SA\u0027 ... est remplac\u00E9e par une r\u00E9f\u00E9rence \u00E0 \u0027Wallonie Entreprendre SA\u0027",
"value": "remplacement de la r\u00E9f\u00E9rence \u00E0 \u0027Soci\u00E9t\u00E9 R\u00E9gionale d\u0027Investissement de Wallonie SA\u0027 par \u0027Wallonie Entreprendre SA\u0027 dans les statuts",
"object": null,
"subject": "e1"
},
{
"type": "statute_amendment",
"quote": "Quatri\u00E8me r\u00E9solution ... les articles 11, 14, 15 et 45 des statuts sont libell\u00E9s comme suit",
"value": "coordination des articles 11, 14, 15 et 45 des statuts",
"object": null,
"subject": "e1"
},
{
"type": "officer_resignation",
"quote": "Sixi\u00E8me r\u00E9solution ... accepter la d\u00E9mission des administrateurs actuels ... La soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e BioPharma Management and Consulting (administrateur investisseur)",
"value": {
"role": "administrateur investisseur"
},
"object": null,
"subject": "e4"
},
{
"type": "officer_resignation",
"quote": "Sixi\u00E8me r\u00E9solution ... accepter la d\u00E9mission ... La soci\u00E9t\u00E9 anonyme Sparaxis (administrateur minoritaire)",
"value": {
"role": "administrateur minoritaire"
},
"object": null,
"subject": "e6"
},
{
"type": "officer_resignation",
"quote": "Sixi\u00E8me r\u00E9solution ... accepter la d\u00E9mission ... La soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e A Q Invest (administrateur minoritaire)",
"value": {
"role": "administrateur minoritaire"
},
"object": null,
"subject": "e8"
},
{
"type": "officer_resignation",
"quote": "Sixi\u00E8me r\u00E9solution ... accepter la d\u00E9mission ... M. Stefan Braam (CEO)",
"value": {
"role": "administrateur"
},
"object": null,
"subject": "e10"
},
{
"date": "2024-03-20",
"type": "officer_appointment",
"quote": "Sixi\u00E8me r\u00E9solution ... nomination comme administrateurs non statutaires de : M. Tim van Biesen ... en tant qu\u0027administrateur investisseur",
"value": {
"role": "administrateur investisseur",
"start_date": "2024-03-20"
},
"object": null,
"subject": "e11",
"_value_raw": {
"role": "administrateur investisseur",
"start_date": "20 mars 2024"
}
},
{
"date": "2024-03-20",
"type": "officer_appointment",
"quote": "Sixi\u00E8me r\u00E9solution ... nomination ... La soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e BioPharma Management and Consulting ... en tant qu\u0027administrateur minoritaire",
"value": {
"role": "administrateur minoritaire",
"start_date": "2024-03-20"
},
"object": null,
"subject": "e4",
"_value_raw": {
"role": "administrateur minoritaire",
"start_date": "20 mars 2024"
}
},
{
"type": "permanent_representative",
"quote": "laquelle a d\u00E9sign\u00E9 en qualit\u00E9 de repr\u00E9sentant permanent Denis Bedoret",
"value": null,
"object": "e4",
"subject": "e5"
},
{
"date": "2024-03-20",
"type": "officer_appointment",
"quote": "Sixi\u00E8me r\u00E9solution ... nomination ... Monsieur Gustavo Mahler ... en tant qu\u2019administrateur ex\u00E9cutif",
"value": {
"role": "administrateur ex\u00E9cutif",
"start_date": "2024-03-20"
},
"object": null,
"subject": "e12",
"_value_raw": {
"role": "administrateur ex\u00E9cutif",
"start_date": "20 mars 2024"
}
},
{
"date": "2024-03-20",
"type": "officer_appointment",
"quote": "Sixi\u00E8me r\u00E9solution ... Monsieur Gustavo Mahler ... en tant que ... \u0027Chief Executive Officer\u0027",
"value": {
"role": "Chief Executive Officer",
"start_date": "2024-03-20"
},
"object": null,
"subject": "e12",
"_value_raw": {
"role": "Chief Executive Officer",
"start_date": "20 mars 2024"
}
},
{
"date": "2024-03-20",
"type": "officer_appointment",
"quote": "Sixi\u00E8me r\u00E9solution ... nomination ... Monsieur Stefan Braam ... en tant qu\u2019administrateur ex\u00E9cutif",
"value": {
"role": "administrateur ex\u00E9cutif",
"start_date": "2024-03-20"
},
"object": null,
"subject": "e10",
"_value_raw": {
"role": "administrateur ex\u00E9cutif",
"start_date": "20 mars 2024"
}
},
{
"date": "2024-03-20",
"type": "officer_appointment",
"quote": "Septi\u00E8me r\u00E9solution ... nommer Monsieur G\u00E9ry Lefebvre ... en tant qu\u2019observateur au sein du conseil d\u2019administration",
"value": {
"role": "observateur",
"start_date": "2024-03-20"
},
"object": null,
"subject": "e13",
"_value_raw": {
"role": "observateur",
"start_date": "20 mars 2024"
}
},
{
"type": "power_of_attorney",
"quote": "Huiti\u00E8me r\u00E9solution ... confier un pouvoir sp\u00E9cial \u00E0 Timothy Speelman, Nathalie Locht ou tout autre avocat du cabinet d\u2019avocats AKD ... \u00E0 l\u0027effet de remplir toute formalit\u00E9 administrative ...",
"value": "remplir toute formalit\u00E9 administrative relative \u00E0 la soci\u00E9t\u00E9 aupr\u00E8s des guichets d\u2019entreprises, du greffe du tribunal d\u2019entreprise, et des services de la taxe sur la valeur ajout\u00E9e, de compl\u00E9ter le registre des actions et le signer",
"object": "e1",
"subject": "e14"
}
],
"act_meta": {
"outcome": "clean",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 56423,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0565.979.162",
"kind": "company",
"name": "Ncardia Holding",
"attrs": {
"seat": "Rue Edouard Belin 2, 1435 Mont-Saint-Guibert",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
}
},
{
"id": "e2",
"kbo": null,
"kind": "person",
"name": "Morgane DEVRIESE",
"attrs": {
"address": "Schaerbeek (Bruxelles)-second canton"
}
},
{
"id": "e3",
"kbo": null,
"kind": "company",
"name": "MASELIS \u0026 DEVRIESE, Notaires Associ\u00E9s",
"attrs": {
"seat": "Boulevard Lambermont 336"
}
},
{
"id": "e4",
"kbo": "0664.691.906",
"kind": "company",
"name": "BioPharma Management and Consulting",
"attrs": {
"seat": "5650 Clermont, rue de Viscourt 2",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
}
},
{
"id": "e5",
"kbo": null,
"kind": "person",
"name": "Denis Bedoret",
"attrs": {
"address": "si\u00E8ge de la soci\u00E9t\u00E9"
}
},
{
"id": "e6",
"kbo": null,
"kind": "company",
"name": "Sparaxis",
"attrs": {
"legal_form": "Soci\u00E9t\u00E9 anonyme"
}
},
{
"id": "e7",
"kbo": null,
"kind": "person",
"name": "Christina Franssen",
"attrs": {
"address": "si\u00E8ge de la soci\u00E9t\u00E9"
}
},
{
"id": "e8",
"kbo": null,
"kind": "company",
"name": "A Q Invest",
"attrs": {
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "Alain Parthoens",
"attrs": {
"address": "si\u00E8ge de la soci\u00E9t\u00E9"
}
},
{
"id": "e10",
"kbo": null,
"kind": "person",
"name": "Stefan Braam",
"attrs": {
"address": "si\u00E8ge de la soci\u00E9t\u00E9"
}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Tim van Biesen",
"attrs": {
"address": "si\u00E8ge de la soci\u00E9t\u00E9"
}
},
{
"id": "e12",
"kbo": null,
"kind": "person",
"name": "Gustavo Mahler",
"attrs": {
"address": "si\u00E8ge de la soci\u00E9t\u00E9"
}
},
{
"id": "e13",
"kbo": null,
"kind": "person",
"name": "G\u00E9ry Lefebvre",
"attrs": {
"address": "si\u00E8ge de la soci\u00E9t\u00E9"
}
},
{
"id": "e14",
"kbo": null,
"kind": "person",
"name": "Timothy Speelman",
"attrs": {}
},
{
"id": "e15",
"kbo": null,
"kind": "person",
"name": "Nathalie Locht",
"attrs": {}
},
{
"id": "e16",
"kbo": null,
"kind": "org",
"name": "AKD",
"attrs": {
"seat": "place du Champ de Mars 5, 1050 Ixelles"
}
}
]
}| Officiële naamFR | BioPharma Management and Consulting |
| AfkortingFR | BM&C |
| HandelsnaamFR | BioPharma Management and Consulting |